Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

JCOG1801: A Phase III Randomized Controlled Trial Comparing Surgery Plus Adjuvant Chemotherapy With Preoperative Chemoradiotherapy Followed by Surgery Plus Adjuvant Chemotherapy for Locally Recurrent Rectal Cancer (RC-SURVIVE Study)

NCT04288999 is registered in ClinicalTrials.gov with National Cancer Center Hospital East as lead sponsor.

NCT NCT04288999
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04288999 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
JCOG1801: A Phase III Randomized Controlled Trial Comparing Surgery Plus Adjuvant Chemotherapy With Preoperative Chemoradiotherapy Followed by Surgery Plus Adjuvant Chemotherapy for Locally Recurrent Rectal Cancer (RC-SURVIVE Study)
Lead sponsor
National Cancer Center Hospital East
Phase
Phase 3
Overall status
Recruiting
Start date
October 1, 2019
Completion date
October 31, 2028
Enrollment
110 (estimated)
Sites
45

Conditions

As the registry lists them; a condition with its own page is linked.

rectal cancer recurrent